Digest Réseau Comment ça marche
Réseau
/
Sociétés
VE
Non vérifié

VERAXA Biotech GmbH

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieFinanceFonds d'investissementPublicité/Marketing/Médias/Communication

8 communiqués de presse

Voir tous les communiqués de presse
24/06/2026
Biotechnologie
Annonces Économiques
Publicité/Marketing/Médias/Communication
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
Source
VERAXA Biotech GmbH
Émetteur
GLOBENEWSWIRE
1.00
0
18/06/2026
Biotechnologie
Annonces Économiques
Médecine Santé Bien-être
Publicité/Marketing/Médias/Communication
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
Source
VERAXA Biotech GmbH
Émetteur
GLOBENEWSWIRE
1.00
0
10/06/2026
Biotechnologie
Finance
Fonds d'investissement
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
Source
VERAXA Biotech GmbH
Émetteur
GLOBENEWSWIRE
1.00
0
27/05/2026
Biotechnologie
Finance
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
Source
VERAXA Biotech GmbH
Émetteur
GLOBENEWSWIRE
1.00
0
01/03/2026
Biotechnologie
Finance
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
Source
VERAXA Biotech GmbH
Émetteur
GLOBENEWSWIRE
1.00
0
30/09/2025
Biotechnologie
Annonces Économiques
Management/Organisation d'Entreprise
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
Source
VERAXA Biotech GmbH
Émetteur
GLOBENEWSWIRE
1.00
0
04/05/2025
Biotechnologie
Management/Organisation d'Entreprise
Fonds d'investissement
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
Source
VERAXA Biotech GmbH
Émetteur
GLOBENEWSWIRE
1.00
0
22/04/2025
Biotechnologie
Fonds d'investissement
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
Source
VERAXA Biotech GmbH
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0